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OBJECTIVE — To examine the effect of a lifestyle intervention to produce weight loss and
increased physical ﬁtness on use and cost of medications to treat cardiovascular disease (CVD)
risk factors in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Look AHEAD is a multicenter randomized
controlledtrialof5,145overweightorobeseindividualswithtype2diabetes,aged45–76years.
An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and
maintain weight loss through decreased caloric intake and increased physical activity was com-
pared with a diabetes support and education (DSE) condition. Medications prescribed to treat
diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication
costs were conservatively estimated using prices from a national online pharmacy.
RESULTS — Participants randomized to an ILI had signiﬁcantly greater improvements in
CVD risk parameters and reduced medication use and cost compared with those assigned to
DSE.At1year,averagenumberofmedicationsprescribedtotreatCVDriskfactorswas3.11.8
for the ILI group and 3.6  1.8 for the DSE group (P  0.0001), with estimated total monthly
medicationcostsof$143and$173,respectively(P0.0001).DSEparticipantsmeetingoptimal
care goals at 1 year were taking an average of 3.8  1.6 medications at an estimated cost of
$194/month. ILI participants at optimal care required fewer medications (3.2  1.7) at lower
cost ($154/month) (P  0.001).
CONCLUSIONS — At 1 year, ILI signiﬁ-
cantly improved CVD risk factors, while at the
same time reduced medication use and cost.
Continuedinterventionandfollow-upwillde-
terminewhetherthesechangesaremaintained
and reduce cardiovascular risk.
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T
ype 2 diabetes is one of the most
signiﬁcantpublichealthconcernsin
the U.S. due to its prevalence and
adverseimpactonlifeexpectancy,quality
of life, and cost. The increasing preva-
lence of obesity and type 2 diabetes in the
U.S. further heightens the importance of
diabetes as a chronic public health dis-
ease. Forecasts based on data from na-
tional health surveys ominously predict
that continuation of current trends in
obesity and diabetes will signiﬁcantly and
adversely impact the rate of future im-
provements in U.S. life expectancy and
quality of life (1).
The excess morbidity and mortality
experienced by people with type 2 diabe-
tes is primarily due to increased cardio-
vascular disease (CVD) risk, and this risk
is in turn driven by the triad of hypergly-
cemia, hypertension, and hyperlipidemia
(2). Appropriately, interventions to re-
duce the adverse health outcomes of type
2 diabetes are primarily directed at these
three CVD risk factors, and speciﬁc pa-
tient goals for parameters of hyperglyce-
mia (A1C), hypertension (blood
pressure), and hyperlipidemia (primarily
LDL cholesterol) have been promulgated
by various professional organizations
(2,3).
Currently, only a minority of people
with type 2 diabetes appear to be achiev-
ing optimal-care goals for CVD risk man-
agement(4).Lifestylemeasuresincluding
weight loss and increased physical activ-
ity have been shown to improve CVD risk
parameters and are therefore the initial
interventions recommended for achiev-
ing glycemic, blood pressure, and lipid
goals(5).However,inpractice,mostpeo-
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lifestyle changes on a long-term basis and
ultimately require multiple pharmaco-
logic agents to achieve currently recom-
mended treatment goals (6–8).
Unfortunately,thispolypharmacyisasso-
ciated with decreased quality of life, in-
creasedriskofadversemedicationeffects,
increased medication use, higher costs,
and higher monitoring expenses (9,10).
Severalstudies(11–13)ofweightloss
interventionsinpeoplewithtype2diabe-
tes have reported reductions in medica-
tion use and/or cost. These studies have
typically been uncontrolled weight loss
interventions applied to small groups of
patients. Beneﬁts have primarily been
seen in diabetes medication require-
ments, with usually smaller effects when
assessed on medications prescribed for
treatment of hypertension and hyperlip-
idemia. These studies support the
premise that effective programs for peo-
plewithtype2diabetesthatachievelong-
term weight loss and increase physical
activity hold the promise of improving
cardiovascular risk parameters while
minimizing the use of pharmacologic
agents.
Look AHEAD (Action for Health and
Diabetes) is an National Institutes of
Health–funded long-term (up to 11.5
years) clinical trial studying the effect of
an intensive lifestyle intervention (ILI) on
CVD morbidity and mortality in people
with type 2 diabetes. The 1-year results of
the Look AHEAD ILI on weight loss, gly-
cemic control, blood pressure, lipid pa-
rameters, and medication use were
recently reported (14). In this report, we
examine the effect of the Look AHEAD
intervention on medication requirements
and estimated medication costs to treat
CVD risk factors in the Look AHEAD
cohort.
RESEARCH DESIGN AND
METHODS— Trial design, methods,
and baseline characteristics of the Look
AHEAD study cohort have been previ-
ouslydescribed(15,16).InLookAHEAD,
5,145 overweight or obese people with
type 2 diabetes were recruited in 16 cen-
ters in the U.S. Participants were aged
45–76 years, had a BMI 25 kg/m
2 (27
kg/m
2 if taking insulin), A1C 11%,
blood pressure 160/100 mmHg, and
fasting triglyceride level 600 mg/dl.
Participants had to successfully complete
a baseline maximal graded exercise test
reaching a workload of at least four met-
abolic equivalents (METS).
Interventions
Participants were randomly assigned to a
usual-care cohort, which received a pro-
gram of general diabetes support and ed-
ucation (DSE), or the ILI cohort, which
receivedaprogramofdiet,behaviormod-
iﬁcation, and increased physical activity
with goals of a minimum weight loss of
7% of initial body weight and at least 175
min/week of moderate physical activity
(e.g., walking). The initial year of the ILI
usedfrequentindividualandgroupmeet-
ings with intervention teams that in-
cluded registered dietitians, behavior
psychologists,andexercisespecialists.To
assist participants in reducing caloric in-
take, participants were prescribed por-
tion-controlleddietsthatincludedtheuse
of meal-replacement products. Dietary
counseling included information on
healthy diet composition, including ade-
quate intake of fruits and vegetables and
avoidanceofexcessivecaloricintakefrom
fat. After 6 months, participants who had
difﬁculty meeting study weight loss goals
received additional study intervention in-
cludingadditionalbehaviorstrategiesand
use of the weight loss medication orlistat
in accord with speciﬁc study protocols.
All study participants received a general
diabetes education session prior to ran-
domization. The DSE cohort was offered
three additional diabetes education ses-
sions during the ﬁrst year. Informed con-
sent was obtained from all participants
before screening and at enrollment, con-
sistent with the Helsinki Declaration and
the guidelines of each center’s institu-
tional review board.
Clinical care
All participants in Look AHEAD were re-
quired to have a primary physician or
physiciansprovidingdiabetesandgeneral
medical care. Participants and their phy-
sicians were provided results of the par-
ticipant’sbaselineweight,bloodpressure,
A1C, fasting lipid values, serum creati-
nine, urinary albumin-to-creatinine ratio
from spot urine samples, and results of
thebaselinemaximalgradedexercisetest.
Allmedicalmanagementandanychanges
in medications were made by the partici-
pant’s primary physician, with the excep-
tion of temporary reductions in certain
hyperglycemic medications during peri-
ods of intensive weight loss intervention
for the ILI cohort. These temporary ad-
justments were made by Look AHEAD
study physicians and nurses using a stan-
dard protocol in order to prevent serious
hypoglycemia during aggressive caloric
reduction. In these instances, the study
protocol provided that hyperglycemic
medications would be returned to the
original regimen when the period of the
intensive caloric restriction was com-
pleted (16).
Assessments
Baseline and 1-year assessments were
made as previously described and in-
cluded subject height, weight, seated
blood pressure after a 5-min rest, A1C,
and fasting lipid levels (14). Laboratory
analyses were conducted by the central
biochemistry laboratory (Northwest
LipidResearchLaboratories,Universityof
Washington, Seattle, WA). Cardiovascu-
larﬁtnesswasassessedasestimatedMETS
during baseline and 1-year treadmill ex-
ercise tests when 80% of age-predicted
maximal heart rate was attained.
Participants brought all prescription
medicationstothebaselineand1-yearvisits
toinsurerecordingaccuracy.Studystaffen-
tered prescription medications into the
study database by medication name, but
speciﬁcmedicationdosagewasnotentered.
Medication costs were estimated as the cost
ofa1-monthsupplyofmedicationas listed
on the Web site of a national online
pharmacy (www.walgreens.com/library/
ﬁnddrug/druginfosearch.jsp) (online
appendix 1, available at http://care.
diabetesjournals.org/cgi/content/full/dc09-
2090/DC1) on 1 November 2007.
Whencostvariedbydrugdose,ados-
age of 50% of the maximal recom-
mended or effective dose was used. For
diabetes medications, medication-
speciﬁc drug costs were used. For blood
pressure and lipid medications, the class
of medication, but not the speciﬁc drug,
was available from the database; there-
fore, a representative medication from
each drug class was arbitrarily selected
and the cost for this medication was as-
signed as the drug cost for drugs in this
class.Genericdrugcostswereusedwhen-
ever an appropriate generic drug was
available.
Participants were deﬁned to be at op-
timal care at their Look AHEAD baseline
or 1-year visit if they met all three of the
following criteria at the visit: 1) A1C
7%, 2) blood pressure 130/80
mmHg, and 3) fasting LDL cholesterol
100 mg/dl (5).
Statistical methods
Differencesbetweenparticipantsassigned
to the ILI and DSE treatments were com-
pared at baseline and 1-year using Stu-
Look AHEAD study medication costs and CVD risk
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continuous variables and a 
2 test for cat-
egorical variables. Comparison of medi-
cation costs between the two groups was
assessed using the Wilcoxon rank sum
test for two-sample medians.
RESULTS
Participants’ baseline characteristics
Of 5,145 individuals who were random-
ized into the trial, 4,998 (97%) had com-
plete data to determine medication use at
baseline (online appendix Fig. 1). As pre-
viously reported, 4,959 participants at-
tended the 1-year exam (14). Of these,
4,358 (88%) had complete data at 1-year
to determine medication use. The per-
centage of participants with evaluable
data did not differ between the two
groupseitheratbaselineoryear1(Fig.1).
Table 1 shows characteristics of the
two groups at baseline and year 1. As pre-
viously reported, the groups were similar
atbaseline,butat1-yeartheILIgrouphad
signiﬁcantly greater weight loss (8.7 vs.
0.8 kg), lower BMI, and signiﬁcantly
greater ﬁtness level than the DSE group
(Table 1) (14).
Changes in medications and
cardiovascular risk parameters
Table 1 and online appendix Fig. 2 show
CVD risk parameters and related medica-
tion use by participants at baseline and 1
year by treatment group. At baseline,
medication use was not different between
the groups. At 1 year, medication use for
ILI was signiﬁcantly lower than DSE (Ta-
ble 1 and online appendix Fig. 2). Al-
though medication use was less for all
three risk factor categories for ILI com-
pared with DSE participants, the differ-
ence was most pronounced for diabetes
medications. At 1 year, 52% of DSE par-
ticipants were taking two or more diabe-
tes medications compared with only 37%
of ILI participants (online appendix Fig.
2). Also at 1 year, almost 25% of ILI par-
ticipants were taking no diabetes medica-
tions compared with only 12% of DSE
participants. Insulin was prescribed for
15 and 16% of ILI and DSE participants,
respectively, at baseline (P  0.18) and
13 and 17%, respectively, at 1-year (P 
0.0001). Medication use for treatment of
hypertension and hyperlipidemia was
also lower at 1 year for ILI participants
comparedwithDSEsubjects(Table1and
online appendix Fig. 2), although for hy-
pertensivemedicationsthedifferencewas
notstatisticallysigniﬁcant(Table1).After
1 year of the Look AHEAD intervention,
ILI participants were taking an average of
3.1  1.8 medications for treatment of
diabetes, hypertension, and hyperlipid-
emia compared with 3.6  1.8 medica-
tions for DSE participants (P  0.0001).
Table1alsoshowsestimatedmonthly
medication cost by risk factor category
and total cost for each group at baseline
and 1 year. At baseline, combined mean
(median) medication costs for the three
risk categories were approximately $155
($130) per month and were not different
between the two groups (P  0.44 for
comparison of medians). At 1 year, total
medicationcostsactuallydecreasedinthe
ILI group compared with baseline but in-
creasedintheDSEgroup.Mean(median)
totalmedicationcostsat1yearwere$143
($120) and $173 ($152) for ILI and DSE,
respectively (P  0.0001 for comparison
of medians). This cost difference was pri-
marily due to signiﬁcantly lower cost of
diabetes medications for ILI compared
withDSE.Thiazolidinedionemedications
are particularly expensive and were pre-
Table 1—All participants: characteristics, cardiovascular risk parameters, medication use, and monthly cost at baseline and 1 year
Baseline
P value
Year 1
P value ILI DSE ILI DSE
n 2,496 2,502 0.93 2,182 2,176 0.93
Women (%) 1,480 (59) 1,491 (60) 0.84 1,301 (60) 1,288 (59) 0.80
Age at randomization (years) 59  75 9  7 0.13 — — —
Duration of diabetes (years) 7  77  6 0.62 — — —
BMI (kg/m
2) 35.9  6.0 36.0  5.8 0.42 32.8  6.1 35.7  5.9 0.0001
Fitness (METS) 5.2  1.5 5.1  1.5 0.07 6.2  2 5.4  1.6 0.0001
Diabetes
A1C (%) 7.3  1.1 7.3  1.2 0.07 6.6  1.0 7.1  1.2 0.0001
Number of prescribed medications 1.5  0.9 1.5  0.9 0.53 1.2  0.9 1.6  0.9 0.0001
Monthly cost ($) 87 (55) 88 (55) 0.74 72 (33) 98 (55) 0.0001
Hypertension
Systolic blood pressure (mmHg) 128  17 130  17 0.011 122  17 126  17 0.0001
Diastolic blood pressure (mmHg) 70  97 0  10 0.10 67  96 8  10 0.0001
Number of prescribed medications 1.3  1.1 1.3  1.1 0.91 1.3  1.1 1.4  1.1 0.19
Monthly cost ($) 36 (23) 37 (23) 0.55 35 (28) 38 (65) 0.11
Hyperlipidemia
LDL cholesterol (mg/dl) 112  32 112  32 0.91 107  32 106  32 0.54
HDL cholesterol (mg/dl) 43  12 43  12 0.99 47  13 45  12 0.0001
Triglycerides (mg/dl) 182  116 180  118 0.59 152  93 166  95 0.0001
Non-HDL cholesterol (mg/dl) 148  38 147  37 0.53 137  37 139  36 0.06
Number of prescribed medications 0.5  0.6 0.5  0.6 0.88 0.5  0.6 0.6  0.6 0.003
Monthly cost ($) 32 (0) 32 (0) 0.96 36 (24) 38 (24) 0.008
Total medications
Number of prescribed medications 3.3  1.8 3.3  1.8 0.72 3.1  1.8 3.6  1.8 0.0001
Monthly cost ($) 155 (129) 157 (134) 0.44 143 (120) 173 (152) 0.0001
Data are mean  SD or frequency (%) and monthly cost data are mean (median), unless otherwise speciﬁed. Fitness is exercise level attained at 80% of
age-predicted maximal heart rate.
Fenney and Associates
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participants,respectively,atbaseline(P
0.24) and 22 and 31%, respectively, at 1
year (P  0.0001). Median costs of blood
pressure and lipid medications were also
lowerinILIcomparedwithDSEat1year,
although the differences were smaller
and, in the case of blood pressure medi-
cations, was not statistically signiﬁcant.
Participants meeting optimal-care
goals
We also analyzed cardiovascular risk pa-
rameters and medication costs for the
subgroup of participants who met opti-
mal-care goals for diabetes, blood pres-
sure, and lipid control (Table 2). As
previously reported, 10% of partici-
pants in both the ILI and DSE groups met
all three optimal-care goals at baseline
(Table 2) (14). At study entry, partici-
pants at optimal care had a shorter dura-
tion of diabetes, had lower BMI, and were
more ﬁt than participants not at optimal
care (data not shown). Medication use
andcostwasslightlyhigheratbaselinefor
participants meeting optimal-care goals
compared with the overall study cohorts.
As shown in Table 2, cardiovascular
risk parameters, medication use, and cost
were not different between the two opti-
mal-care groups at baseline. After 1 year
of the Look AHEAD intervention, more
ILI participants met optimal-care goals,
and ILI participants at optimal care had
signiﬁcantly lower A1C, systolic blood
pressure, triglycerides, and non-HDL
cholesterol and higher HDL cholesterol
compared with the DSE optimal-care co-
hort. LDL cholesterol was lower in both
groups at 1 year compared with baseline
and was not different between groups.
Notably, medication use and cost de-
creased in the ILI optimal-care group at 1
year compared with baseline but in-
creased in the DSE group. At 1 year, av-
erage medication costs to reach optimal-
care goals were almost $200/month for
DSE participants compared with approx-
imately $155/month for the ILI cohort
(median costs $177 vs. $128, respec-
tively, P  0.001).
CONCLUSIONS— We found that at
randomization into the Look AHEAD
study,participantsweretakinganaverage
of 3.3 medications, costing an estimated
$155/month for management of the CVD
risk factor triad of hyperglycemia, hyper-
tension,andhyperlipidemia.Despitethis,
only 10% of participants at entry into the
study were meeting optimal goals for di-
abetes, blood pressure, and lipid control.
After 1 year of an ILI focused on weight
loss and increased physical activity, par-
ticipants in the ILI group had signiﬁcant
improvements in A1C, blood pressure,
and lipid parameters, while at the same
time reduced medication use and cost.
The DSE group experienced a more mod-
estimprovementintheseparameters,and
this occurred in the setting of increased
medication use and cost. The total cost of
diabetes, blood pressure, and lipid pre-
scription medications for DSE partici-
pants at 1 year was an estimated $173/
month compared with approximately
$143/month for ILI participants. Com-
pared with baseline, medication costs in-
creased by 10% in the DSE group and
decreased by almost 10% in ILI partici-
pants. At 1 year, almost 40% of ILI par-
ticipants were taking two or fewer total
medicationstomanagetheirdiabetes,hy-
pertension, and hyperlipidemia com-
pared with only 28% of DSE participants.
Over 50% of DSE participants were pre-
scribedfourormoremedicationsat1year
compared with 41% of ILI participants.
Participants meeting optimal-care
goals at baseline were taking more medi-
cations with increased cost relative to the
overall study cohort. The Look AHEAD
intervention more than doubled the per-
centageofparticipantsachievingoptimal-
caregoals,whileatthesametimereduced
medication use and cost.
The beneﬁcial effects of the ILI inter-
vention were seen primarily in diabetes
Table 2—Participants meeting optimal-care goals: cardiovascular risk parameters, medication use, and monthly cost at baseline and 1 year
Baseline
P value
Year 1
P value ILI DSE ILI DSE
n (% of total cohort) 269 (11) 239 (10) 0.93 517 (24) 359 (16) 0.0001
Diabetes
A1C (%) 6.3  0.4 6.3  0.5 0.92 6.1  0.5 6.3  0.4 0.0001
Number of prescribed medications 1.3  0.9 1.4  0.9 0.28 1.1  0.5 1.5  0.9 0.001
Monthly cost ($) 74 (33) 86 (33) 0.13 70 (33) 101 (55) 0.001
Hypertension
Systolic blood pressure (mmHg) 114  10 115  10 0.68 112  10 114  10 0.0001
Diastolic blood pressure (mmHg) 65  86 5  8 0.90 63  86 4  8 0.20
Number of prescribed medications 1.4  1.1 1.3  1.1 0.34 1.4  1.1 1.5  1.1 0.05
Monthly cost ($) 40 (24) 35 (24) 0.39 37 (24) 40 (24) 0.08
Hyperlipidemia
LDL cholesterol (mg/dl) 80  15 81  14 0.49 80  15 79  14 0.84
HDL cholesterol (mg/dl) 43  12 43  12 0.99 47  13 45  12 0.0001
Triglycerides (mg/dl) 183  116 180  118 0.40 152  93 166  95 0.0001
Non-HDL cholesterol (mg/dl) 114  24 117  24 0.26 107  23 110  21 0.03
Number of prescribed medications 1.4  1.1 1.3  1.1 0.48 1.4  1.1 1.5  1.1 0.009
Monthly cost ($) 48 (65) 52 (65) 0.62 47 (65) 54 (65) 0.008
Total medications
Number of prescribed medications 3.4  1.8 3.5  1.7 0.86 3.2  1.7 3.8  1.6 0.001
Monthly cost ($) 163 (139) 172 (142) 0.86 154 (128) 194 (177) 0.001
DataaremeanSDorfrequency(%)andmonthlycostdataaremean(median),unlessotherwisespeciﬁed.Participantsatoptimalcaredeﬁnedasparticipantswith
A1C 7%, blood pressure 130/80 mmHg, and LDL cholesterol 100 mg/dl as measured at the applicable study visit.
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ther improvement in LDL cholesterol val-
ues was observed. This latter observation
is not surprising since weight reduction
programs with diet and exercise typically
show greater reductions in triglyceride
levels with more modest reductions in to-
tal and LDL cholesterol (17). Non-HDL
cholesterol may be a better predictor of
cardiovascular risk in people with type 2
diabetes than LDL cholesterol (18), and
current lipid guidelines suggest targeting
non-HDL cholesterol as a secondary goal
after LDL cholesterol (5). At 1 year, non-
HDL cholesterol was lower in the ILI co-
hortcomparedwiththeDSEsubjects,and
this was achieved without additional
medication use.
Our data on medication cost should
be viewed as general estimates of the cost
individualswithtype2diabetesmightin-
cur if they paid out of pocket for their
diabetes, blood pressure, and lipid medi-
cations. We did not factor in medication
dosageorindividualinsulinrequirements
in the cost estimates. For blood pressure
and lipid medications, we assigned a sin-
gledrugcostforeachdrugclassusingcost
data for a representative drug from that
class. We used cost data for generic drugs
whenever possible and assumed half-
maximal drug dosage; therefore, our esti-
mates very likely underestimate cost. As
improvements in diabetes, blood pres-
sure, and lipid parameters might prompt
participants’ personal physicians to re-
duce medication doses rather than dis-
continue medications altogether, our
estimates would tend to underestimate
cost differences between the ILI and DSE
groups.
Our analysis is limited to a compari-
son of medication costs between ILI and
DSE participants. The analysis does not
include assessment of other costs associ-
ated with the respective interventions.
Both the ILI and DSE participants re-
ceived counseling related to healthy life-
style and general diabetes care.
Counseling sessions were more intensive
and frequent for ILI participants and
thereforewouldhavegreatercost.ILIpar-
ticipants also were provided with meal-
replacement products to assist in weight
loss, and some received the weight loss
medication orlistat. This would also add
totheoverallcostoftheILIduringthe1st
year. On the other hand, we did not in-
clude in medication cost–related ex-
penses such as cost of supplies for insulin
administration, home glucose testing,
and laboratory expenses related to medi-
cation monitoring. At 1 year, ILI partici-
pants were less likely to be using insulin
and were taking fewer medications over-
all compared with DSE participants. It is
therefore likely that these related ex-
penses would also be lower for the ILI
cohort compared with DSE. A compari-
son of intervention costs between the ILI
and DSE approaches would need to be
interpreted in the context of an overall
cost/beneﬁt analysis, which of necessity
must await the completion of the Look
AHEAD trial.
Peoplewithtype2diabetesdieonav-
erage 8 years earlier than their nondia-
betic counterparts, primarily due to a
two- to fourfold increased risk of CVD
(2,19). Pharmacologic treatment of hy-
perglycemia, hypertension, and hyperlip-
idemia has been shown to reduce CVD
riskinpeoplewithdiabetes,andthistriad
is now the cornerstone of optimal-care
goals in the chronic disease management
of type 2 diabetes (5). Clinical trials and
clinical experience show that polyphar-
macy is the rule in meeting current opti-
mal-care goals (6,8). The term “triple
therapy” has entered the lexicon of clini-
cal diabetes care, and ﬁve or more
prescription drugs are often required
to adequately treat diabetes, hyperten-
sion, and hyperlipidemia (6,20). Unfor-
tunately, polypharmacy comes at a price
of increased cost, side effects, risk of ad-
verse drug interactions, decreased com-
pliance, and decreased quality of life
(9,10,21,22). Moreover, recent results
from the ACCORD (Action to Control
Cardiovascular Risk in Diabetes) trial
raise questions about the beneﬁts of ag-
gressive glycemic control, at least when
achieved through the use of multiple dia-
betes medications (23). At 1 year, DSE
participants in the Look AHEAD study
reaching optimal-care goals were taking,
on average, almost four medications daily
for management of diabetes, hyperten-
sion, and hyperlipidemia at an estimated
cost of almost $200/month. Their ILI op-
timal-care counterparts were taking
slightlymorethanthreemedicationsdaily
at an estimated cost of $155/month.
ThetotalcostofdiabetesintheU.S.in
2007 is estimated at $174 billion, with
$25 billion of this cost attributed to out-
patient retail prescriptions. Diabetes
medications and supplies and medica-
tions to treat the complications of diabe-
tes are estimated at 25% of the medical
expenses attributed to diabetes, making
this the second largest single cost after
hospital inpatient care (24). An effective,
long-termlifestyleinterventionforpeople
with type 2 diabetes that simultaneously
reduces cardiovascular risk parameters
and prescription medication cost would
have major public health implications.
In conclusion, compared with a pro-
gram of general DSE, the Look AHEAD
study ILI program after 1 year resulted in
greater improvements in diabetes, blood
pressure, and lipid parameters, while at
the same time reduced prescription med-
icationrequirementsandcost.Theseben-
eﬁts were seen for both the total study
cohort as well as the subgroup of partici-
pants who met optimal-care goals for the
CVD risk triad of diabetes, hypertension,
and hyperlipidemia. Those participants
meeting optimal-care goals took more
medications with higher cost compared
with the overall study cohort, but like the
total study cohort, their medication re-
quirements and costs were substantially
reduced by the study intervention. If
these changes can be sustained for the
long term, the public health beneﬁts
would be substantial.
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